Abstract
Li–Fraumeni syndrome (LFS) is a rare familial cancer syndrome characterized by early cancer onset, diverse tumor types, and multiple primary tumors. Germ-line TP53 mutations have been identified in most LFS families. A high-frequency single-nucleotide polymorphism, SNP309 (rs2279744), in MDM2 was recently confirmed to be a modifier of cancer risk in several case-series studies: substantially earlier cancer onset was observed in SNP309 G-allele carriers than in wild-type individuals by 7–16 years. However, cancer risk analyses that jointly account for measured hereditary TP53 mutations and MDM2 SNP309 have not been systematically investigated in familial cases. Here, we determined the combined effects of measured TP53 mutations, MDM2 SNP309, and gender and their interactions simultaneously in LFS families. We used the method that is designed for extended pedigrees and structured for age-specific risk models based on Cox proportional hazards regression. We analyzed the cancer incidence in 19 extended pedigrees with germ-line TP53 mutations ascertained through the clinical LFS phenotype. The dataset consisted of 463 individuals with 129 TP53 mutation carriers. Our analyses showed that the TP53 germ-line mutation and its interaction with gender were strongly associated with familial cancer incidence and that the association between MDM2 SNP309 and increased cancer risk was modest. In contrast with several case-series studies, the interaction between MDM2 SNP309 and TP53 mutation was not statistically significant in our LFS family cohort. Our results showed that SNP309 G-alleles were associated with accelerated tumor formation in both carriers and non-carriers of germ-line TP53 mutations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Altshuler D, Daly MJ, Lander ES (2008) Genetic mapping in human disease. Science 322:881–888
Balding DJ (2006) A tutorial on statistical methods for population association studies. Nat Rev Genet 7:781–791
Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Jones PH, Binchy A, Crowther D (1994a) Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li–Fraumeni families. Cancer Res 54:1298–1304
Birch JM, Heighway J, Teare MD, Kelsey AM, Hartley AL, Tricker KJ, Crowther D, Lane DP, Santibanez-Koref MF (1994b) Linkage studies in a Li–Fraumeni family with increased expression of p53 protein but no germline mutation in p53. Br J Cancer 70:1176–1181
Bond GL, Levine AJ (2007) A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene 26:1317–1323
Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591–602
Bonney GE, Lathrop GM, Lalouel JM (1988) Combined linkage and segregation analysis using regressive models. Am J Hum Genet 43:29–37
Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L, Chompret A, Bressac-de PB, Stoppa-Lyonnet D, Bonaiti-Pellie C, Frebourg T (2006) Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li–Fraumeni syndrome. J Med Genet 43:531–533
Bougeard G, Sesboue R, Baert-Desurmont S, Vasseur S, Martin C, Tinat J, Brugieres L, Chompret A, de Paillerets BB, Stoppa-Lyonnet D, Bonaiti-Pellie C, Frebourg T (2008) Molecular basis of the Li–Fraumeni syndrome: an update from the French LFS families. J Med Genet 45:535–538
Brown BW, Costello TJ, Hwang SJ, Strong LC (2005) Generation or birth cohort effect on cancer risk in Li–Fraumeni syndrome. Hum Genet 118:489–498
Chompret A, Brugieres L, Ronsin M, Gardes M, ssarps-Freichey F, Abel A, Hua D, Ligot L, Dondon MG, Bressac-de PB, Frebourg T, Lemerle J, Bonaiti-Pellie C, Feunteun J (2000) P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 82:1932–1937
Devlin B, Risch N (1995) A comparison of linkage disequilibrium measures for fine-scale mapping. Genomics 29:311–322
Fang S, Krahe R, Lozano G, Han Y, Chen W, Post SM, Zhang B, Wilson CD, Bachinski LL, Strong LC, Amos CI (2010) Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations. PLoS One 5:e10813
Gauderman WJ, Faucett CL (1997) Detection of gene–environment interactions in joint segregation and linkage analysis. Am J Hum Genet 61:1189–1199
Genetic Analysis Package (1997) Epicenter Software, Pasadena, California, USA
Greenberg DA (1989) Inferring mode of inheritance by comparison of lod scores. Am J Med Genet 34:480–486
Hwang SJ, Cheng LS, Lozano G, Amos CI, Gu X, Strong LC (2003a) Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet 113:238–243
Hwang SJ, Lozano G, Amos CI, Strong LC (2003b) Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet 72:975–983
Li FP, Fraumeni JF Jr (1969a) Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 43:1365–1373
Li FP, Fraumeni JF Jr (1969b) Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 71:747–752
Lustbader ED, Williams WR, Bondy ML, Strom S, Strong LC (1992) Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. Am J Hum Genet 51:344–356
Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233–1238
Marcel V, Palmero EI, Falagan-Lotsch P, Martel-Planche G, shton-Prolla P, Olivier M, Brentani RR, Hainaut P, Achatz MI (2009) TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li–Fraumeni syndrome: impact on age at first diagnosis. J Med Genet 46:766–772
Nichols KE, Malkin D, Garber JE, Fraumeni JF Jr, Li FP (2001) Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 10:83–87
Ruijs MW, Schmidt MK, Nevanlinna H, Tommiska J, Aittomaki K, Pruntel R, Verhoef S, van’t Veer LJ (2007) The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li–Fraumeni syndrome and related phenotypes. Eur J Hum Genet 15:110–114
Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH (1990) Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome. Nature 348:747–749
Strong LC, Stine M, Norsted TL (1987) Cancer in survivors of childhood soft tissue sarcoma and their relatives. J Natl Cancer Inst 79:1213–1220
Strong LC, Williams WR, Tainsky MA (1992) The Li–Fraumeni syndrome: from clinical epidemiology to molecular genetics. Am J Epidemiol 135:190–199
Varley JM, McGown G, Thorncroft M, Santibanez-Koref MF, Kelsey AM, Tricker KJ, Evans DG, Birch JM (1997) Germ-line mutations of TP53 in Li–Fraumeni families: an extended study of 39 families. Cancer Res 57:3245–3252
Wong P, Verselis SJ, Garber JE, Schneider K, Digianni L, Stockwell DH, Li FP, Syngal S (2006) Prevalence of early onset colorectal cancer in 397 patients with classic Li–Fraumeni syndrome. Gastroenterology 130:73–79
Wu CC, Shete S, Amos CI, Strong LC (2006) Joint effects of germ-line p53 mutation and sex on cancer risk in Li–Fraumeni syndrome. Cancer Res 66:8287–8292
Wu CC, Strong LC, Shete S (2010) Effects of measured susceptibility genes on cancer risk in family studies. Hum Genet 127:349–357
Acknowledgments
This research was supported by the US National Cancer Institute grants R03-CA128103 to Wu CC and P01-CA034936 to Strong LC.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wu, CC., Krahe, R., Lozano, G. et al. Joint effects of germ-line TP53 mutation, MDM2 SNP309, and gender on cancer risk in family studies of Li–Fraumeni syndrome. Hum Genet 129, 663–673 (2011). https://doi.org/10.1007/s00439-011-0957-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00439-011-0957-1